Last updated: September 22, 2025
Sponsor: Hopital of Melun
Overall Status: Completed
Phase
N/A
Condition
Epilepsy (Pediatric)
Epilepsy
Treatment
Isoflurane
Clinical Study ID
NCT05830864
MIR-2023-01
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age > 18 years, hospitalized in ICU between 2016-01-01 and 2023-01-01, sufferingrefractory status epilepticus treated by inhaled Isoflurane as third anticonvulsivetherapy
Exclusion
Exclusion Criteria:
- post-anoxic refractory status epilepticus after cardiac arrest, withdrawal ofconsent for medical data use
Study Design
Total Participants: 66
Treatment Group(s): 1
Primary Treatment: Isoflurane
Phase:
Study Start date:
June 30, 2024
Estimated Completion Date:
September 22, 2025
Study Description
Connect with a study center
Ch Bethune Beuvry
Beuvry, 62660
FranceSite Not Available
Ch Bethune Beuvry
Beuvry 3032903, 62660
FranceSite Not Available
CHU Brest
Brest, 29200
FranceSite Not Available
CHU Brest
Brest 3030300, 29200
FranceSite Not Available
GH Sud Ile de France, Hôpital de Melun-Sénart
Melun, 77000
FranceSite Not Available
GH Sud Ile de France, Hôpital de Melun-Sénart
Melun 2994651, 77000
FranceSite Not Available
CH Toulon - Sainte Musse
Toulon, 83000
FranceSite Not Available
CH Toulon - Sainte Musse
Toulon 2972328, 83000
FranceSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.